Kambiz Yadidi


Mr. Yadidi is Chairman of the Board and Chief Executive Officer of Otitopic, with 25 years management in life science Industry. Prior to the formation of Otitopic, Mr. Yadidi was the founder and CEO of Sinus Dynamics, a specialty pharmacy dedicated to offering acute and chronic sinusitis sufferers a topical intranasal drug delivery form of therapy. While CEO of Sinus Dynamics, he developed a growth strategy that resulted in 43%+ annual growth each year. In January 2012 Sinus Dynamics was successfully sold to a private equity healthcare firm.

Prior to Sinus Dynamics, Mr. Yadidi founded and invested in several successful healthcare businesses. He is an accomplished entrepreneur in the healthcare industry. With over 25 years of experience, he has created several companies and patented several drug delivery devices and advised small to medium-sized businesses evolve into valuable and enduring companies that have made a difference in the healthcare market. His vision coupled with his experience and knowledge has guided him to success.

David Hale

Strategy Advisor

David F. Hale is the Chairman and CEO of Hale BioPharma Ventures, LLC. He is a serial entrepreneur who has been involved in the formation and development of a number of pharmaceutical, biotechnology, diagnostic and medical device companies. These companies include Hybritech, SkinMedica, Gensia, Santarus, Micromet, Neurelis, Neurana Pharmaceuticals, Oncternal Therapeutics and Conatus. His early career was in sales, marketing and general management at Johnson & Johnson and Becton-Dickinson. 

He has also been involved in industry organizations, including CONNECT, the Biotechnology Organization, BIOCOM, the San Diego Economic Development Organization, and many others. He is a Board member and former Chair of Rady Children’s Hospital, Chairman of the Rady Institute of Genomic Medicine and a trustee of the Salk Institute and the University of San Diego.

Jeffrey B. Harris

Vice President and General Counsel

Jeff, a member of the Barton, Klugman and Oetting LLP management committee, has been a partner with the firm since 1999.

 Jeff is a solution-oriented legal, tax and business advisor to emerging and growing companies in connection with mergers and acquisitions, equity financings, real estate, corporate formation and governance, intellectual property licensing, technology licensing and protection, distribution and supplier contracts, and joint venture agreements. He has a straightforward, pragmatic approach to helping businesses with their legal needs. Jeff works with clients in a wide range of industries, including high-tech, med-tech, defense-tech, entertainment, sports, technology and services. 

Jeff also is a Certified Public Accountant and has extensive experience in federal and state income taxation (corporate, partnership and individual), tax-deferred reorganizations, and estate and gift taxation. He also advises clients with respect to structural aspects and ongoing operational, administrative, tax and accounting issues associated with both private and court-supervised trusts and estates. 

Jeff has represented publicly held and private business and individual interests for over 35 years. His experience ranges from serving as tax and business counsel to numerous corporate and partnership entities, including closely-held family businesses and trusts, to investigating transactional fraud and undertaking financial, tax and valuation analysis for those entities.

Dr. Jag Shur, Ph.D.

Chief Scientific Advisor

Dr Jag Shur is a director of Nanopharm Ltd and has managed business operations and the successful growth of Nanopharm. He has over 15 years of experience in the development of orally inhaled and nasal drug products in both industry and academia, having held positions at Profile Therapeutics (Philips), GlaxoSmithKline and the University of Bath. Dr. Shur has a first degree in Chemistry, received his PhD in Inhaled Biopharmaceutics and has authored more than 30 scientific papers.

Dr. Shur’s key vision is to highlight the fundamental role and importance of the physical and chemical sciences in advancing therapies available to treat patients. His research is at the interface of bioengineering, material science, and medicine, with an aim to develop drug delivery investigating bioequivalence of inhaled drug products. With a particular focus on understanding device and formulation factors that may affect in vitro equivalence of dry powder inhalers.

Furthermore, developing formulation approaches to impact regional drug deposition in the lung. Within inhaled drug delivery systems, complex surface interfacial interactions occur between the active pharmaceutical ingredient (API) and excipient material(s), which govern the overall performance and efficacy of the drug product.

James W. Hill, MD, JD

Intellectual Property Attorney

James is a physician, patent attorney, and partner at FisherBroyles LLP, where he practices patent litigation, prosecution, and licensing in the areas of medical devices, biotechnology, software, and pharmaceuticals. He is a cofounder of Highpoint Therapeutics, an oncology startup focused on killing cancer stem cells with nanoencapsulated salinomycin and other agents. 

A graduate of the University of Southern California (USC) School of Medicine, James received residency training in internal medicine and in radiology at the Massachusetts General Hospital and Harvard Medical School, where he was awarded a fellowship in neuroradiology. He completed coursework in the Master of Science in Electrical Engineering program at USC, with an emphasis in signal and image processing. He is a member of the American Society for Clinical Nutrition with a research interest in Alzheimer’s disease and other neurodegenerative diseases. 

James is recommended in Chambers USA and The Legal 500 United States in the area of life sciences and named a leading patent professional in California by IAM Patent 1000 – The World’s Leading Patent Practitioners for both patent litigation and prosecution, and a Top 25 Portfolio Manager by the Daily Journal. He has served on the scientific board of advisors for several life science companies.